The report forecasts the market size out to 2025. In a special section, the report looks at the numbers on how syndromic molecular diagnostics is replacing traditional panel-based ordering of infectious disease tests.
The COVID pandemic is ushering in a new world of infectious disease diagnostics. Infectious disease Dx is changing and will change more in the future. Can a rapidly growing market expand even faster? Find out all about it in this comprehensive report on Syndromic Multiplex Diagnostics.
Are targeted tests for specific pathogens going to be obsolete? Will diagnostics replace physicians? Will Infectious Disease testing move into the Physician's Office or even the Home?
Syndromic testing is proving itself in the market. Players are reporting double-digit growth. Lowering costs, improving outcomes and even helping in the battle against Anti Microbial Resistance. Learn about this market including the issues and outlooks.
The two key trends of Point of Care Testing and Molecular Diagnostics are merging with spectacular success. It could possibly displace most frontline test protocols AND save money at the same time.
Syndromic Testing Recent Developments
QuantuMDx Developing Syndromic Panels for European Launch
Quidel Gains CE Mark for Savanna Analyzer, Respiratory Panel
QuantumDx Gets CE Mark for Rapid PoC PCR System
Bio-Rad Laboratories, Seegene Partner for MDx Development
Baebies to Expand Finder Platform
With Luminex Acquisition, DiaSorin to Broaden MDx Portfolio
Binx Health Targeting Clinics, DTC & OTC With STI Tests
Luminex Lands BARDA Grant to Develop Test for SARS-CoV-2, Flu, RSV